10.1007/s40262-015-0285-z 43 DobsonM
About this article Cite this article Flanagan, J.L., Simmons, P.A., Vehige, J
Imam AM, Jin G, Duggan M, Sillesen M, Hwabejire JO, Jepsen CH, et al
There are several Phase 3 trials evaluating GLP-1s for conditions, such as metabolic dysfunction-associated steatohepatitis (MASH), prediabetes, Alzheimer's disease, diabetic retinopathy and osteoarthritis of the knee (in patients with obesity)
The publication of high-quality mechanistic studies, coupled with small human trials showing functional endocrine and immune effects , has elevated the peptide from fringe curiosity to a serious candidate in the longevity toolkit
If you need further assistance or guidance on other topics, please let me know